Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA.
Drug Metab Dispos. 2010 Jun;38(6):917-22. doi: 10.1124/dmd.109.031161. Epub 2010 Mar 8.
[(11)C]N-desmethyl-Loperamide ([(11)C]dLop) is used in positron emission tomography (PET) to measure the in vivo activity of efflux transporters that block the passage of drugs across the blood-brain barrier. The three most prevalent ATP-binding cassette efflux transporters at the blood-brain barrier are P-glycoprotein (P-gp), multidrug resistance protein 1 (Mrp1), and breast cancer resistance protein (BCRP). We sought to measure the selectivity of dLop among these three transporters. The selectivity of dLop at low concentrations (< or =1 nM) was measured both as the accumulation of [(3)H]dLop in human cells that overexpress each transporter and as the uptake of [(11)C]dLop in brains of mice that lack genes encoding P-gp, Mrp1, or BCRP. The selectivity of dLop at high concentrations (> or =20 microM) was measured as the inhibition of uptake of a fluorescent substrate and the change in cytotoxicity of drugs effluxed at each transporter. Accumulation of [(3)H]dLop was lowest in cells overexpressing P-gp, and the uptake of [(11)C]dLop was highest in brains of mice lacking P-gp. At high concentrations, dLop selectively inhibited P-gp function and also decreased the resistance of only the P-gp-expressing cells to cytotoxic agents. dLop is selective for P-gp among these three transporters, but its activity is dependent on concentration. At low concentrations (< or =1 nM), dLop acts only as a substrate; at high concentrations (> or =20 microM), it acts as both a substrate and an inhibitor (i.e., a competitive substrate). Because low concentrations of radiotracer are used for PET imaging, [(11)C]dLop acts selectively and only as a substrate for P-gp.
[(11)C]N-去甲基洛哌丁胺 ([(11)C]dLop) 用于正电子发射断层扫描 (PET) 来测量阻止药物穿过血脑屏障的外排转运体的体内活性。血脑屏障上最常见的三种三磷酸腺苷结合盒外排转运体是 P-糖蛋白 (P-gp)、多药耐药蛋白 1 (Mrp1) 和乳腺癌耐药蛋白 (BCRP)。我们试图测量 dLop 在这三种转运体中的选择性。在低浓度(≤1 nM)下,dLop 的选择性通过测量每种转运体过度表达的人细胞中 [(3)H]dLop 的积累和缺乏编码 P-gp、Mrp1 或 BCRP 基因的小鼠脑中 [(11)C]dLop 的摄取来衡量。在高浓度(>20 μM)下,dLop 的选择性通过抑制荧光底物的摄取以及每种转运体外排药物的细胞毒性变化来衡量。在过度表达 P-gp 的细胞中,[(3)H]dLop 的积累最低,而在缺乏 P-gp 的小鼠脑中,[(11)C]dLop 的摄取最高。在高浓度下,dLop 选择性地抑制 P-gp 功能,并且仅降低仅表达 P-gp 的细胞对细胞毒性剂的耐药性。dLop 在这三种转运体中对 P-gp 具有选择性,但它的活性取决于浓度。在低浓度(≤1 nM)下,dLop 仅作为底物起作用;在高浓度(>20 μM)下,它既作为底物又作为抑制剂(即竞争性底物)起作用。由于用于 PET 成像的放射性示踪剂浓度较低,[(11)C]dLop 选择性地仅作为 P-gp 的底物起作用。